Bacillus Anthracis Immunoserum Rabbit

The standard adult dosage for Bacillus Anthracis Immunoserum Rabbit is a single weight-based dose administered via intravenous (IV) infusion. For patients weighing 40 kg or more, the recommended dose is 16 mg/kg. For example, a patient weighing 70 kg would receive 1,120 mg. The maximum dose is typically capped based on clinical protocols established by the CDC and FDA. The infusion is usually administered over a period of 90 minutes to minimize the risk of infusion-related reactions.

Bacillus Anthracis Immunoserum Rabbit is approved for use in pediatric patients, including neonates. The dosage is strictly weight-based to ensure safety and efficacy in smaller bodies:

• Children weighing 40 kg or more: 16 mg/kg via IV infusion.
• Children weighing 15 kg to less than 40 kg: 24 mg/kg via IV infusion.
• Children weighing less than 15 kg: 32 mg/kg via IV infusion.

The higher mg/kg dose in smaller children is necessary because pediatric patients typically have a higher clearance rate for monoclonal antibodies compared to adults.

Renal Impairment

No dosage adjustment is required for patients with renal impairment. Because the drug is a large protein eliminated via proteolytic catabolism rather than renal filtration, kidney function does not significantly impact its clearance.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic impairment. The liver's metabolic enzymes (CYP450) are not involved in the elimination of this biological agent.

Elderly Patients

Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, weight-based dosing is generally considered appropriate for this population, provided their cardiovascular status can tolerate the infusion volume.

This medication is administered exclusively by healthcare professionals in a clinical setting (hospital, emergency clinic, or field hospital).

1. 1Premedication: To reduce the risk of infusion reactions and anaphylaxis, patients are often given diphenhydramine (an antihistamine) approximately 30 to 60 minutes before the infusion starts.
2. 2Preparation: The vial must be diluted in 0.9% Sodium Chloride Injection, USP, before administration. The final concentration and volume depend on the patient's weight.
3. 3Infusion: The IV infusion should be administered slowly over 90 minutes. The infusion rate may be slowed or stopped if the patient develops signs of a reaction.
4. 4Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light. They should not be frozen or shaken.

Since Bacillus Anthracis Immunoserum Rabbit is administered as a single dose by a healthcare provider, the risk of a missed dose is minimal. However, in a post-exposure prophylaxis scenario, it is critical to receive the dose as soon as possible after suspected exposure to maximize the chances of neutralizing the toxin before it enters the cells.

There is limited data regarding overdose with this medication. Symptoms of an overdose would likely manifest as exaggerated side effects, particularly hypersensitivity or cardiovascular strain from the infusion volume. In the event of an overdose, treatment is supportive, focusing on managing allergic reactions and maintaining vital signs.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. This medication is administered under strict medical supervision.

Because Bacillus Anthracis Immunoserum Rabbit is a foreign protein (derived from rabbits), the most common side effects are related to the body's immune response to the infusion. Approximately 10% to 20% of patients may experience:

• Headache: This is often described as a dull, throbbing sensation that typically begins during or shortly after the infusion and may last for 24 to 48 hours.
• Pruritus (Itching): Patients may experience generalized itching or localized itching at the injection site. This is usually manageable with antihistamines.
• Upper Respiratory Tract Infections: Some patients report nasal congestion or a sore throat in the days following administration.
• Infusion Site Reactions: This includes redness, swelling, or pain where the IV was inserted.

• Nausea and Vomiting: Mild gastrointestinal distress may occur during the infusion.
• Urticaria (Hives): Raised, itchy welts may appear on the skin, signaling a mild allergic response.
• Cough and Throat Irritation: Some patients experience a dry cough or a feeling of tightness in the throat during the infusion.
• Dizziness: A feeling of lightheadedness, which may be related to the infusion rate or a mild drop in blood pressure.

• Serum Sickness: Since this is a rabbit-derived product, there is a theoretical risk of serum sickness, a delayed immune reaction characterized by fever, joint pain, and rash, occurring 5 to 14 days after administration.
• Lymphadenopathy: Swelling of the lymph nodes as the immune system processes the foreign proteins.

> Warning: Stop taking Bacillus Anthracis Immunoserum Rabbit and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is the most critical risk. Symptoms include difficulty breathing, swelling of the face, lips, or tongue, a rapid drop in blood pressure, and fainting. This can be life-threatening and usually occurs during or immediately after the infusion.
• Severe Bronchospasm: Sudden wheezing or inability to catch your breath.
• Angioedema: Deep swelling under the skin, particularly around the eyes and mouth.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term side effects associated with a single dose of Bacillus Anthracis Immunoserum Rabbit. Because the drug is cleared from the system within a few months, it does not typically cause chronic health issues. However, patients who receive the drug should be monitored for the development of 'anti-drug antibodies' (ADAs), which could potentially make future doses of rabbit-derived medications less effective or more likely to cause an allergic reaction.

WARNING: HYPERSENSITIVITY AND ANAPHYLAXIS

Bacillus Anthracis Immunoserum Rabbit has been associated with severe hypersensitivity reactions, including anaphylaxis. Because it is a rabbit-derived protein, the risk of an allergic reaction is significant. Clinical trials showed that healthy volunteers experienced anaphylaxis at a rate of approximately 1%.

• This medication should only be administered in a healthcare setting by personnel prepared to manage anaphylaxis.
• Patients must be monitored closely during the infusion and for at least one hour after the infusion is complete.
• Premedication with diphenhydramine is strongly recommended.
• If anaphylaxis or a severe hypersensitivity reaction occurs, the infusion must be discontinued immediately and appropriate emergency therapy initiated.

Report any unusual symptoms to your healthcare provider. Even mild symptoms like a rash or itching should be reported immediately during the infusion process.

Bacillus Anthracis Immunoserum Rabbit is a high-alert biological product. Its use is reserved for life-threatening situations involving anthrax. The most important safety consideration is the risk of a foreign protein reaction. Because the drug is manufactured using rabbit serum, the human immune system may recognize it as an invader, leading to a cascade of allergic responses.

Hypersensitivity and Anaphylaxis Risk: The FDA has issued a Black Box Warning for this product due to the risk of life-threatening allergic reactions. In clinical studies, approximately 1% of subjects experienced anaphylaxis. These reactions can occur even in patients who have never been exposed to rabbits or rabbit products before. Medical facilities must have emergency resuscitation equipment, including epinephrine, oxygen, and IV fluids, immediately available during administration.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to rabbits or rabbit-derived products are at a much higher risk. However, even those without known allergies must be treated with extreme caution. The infusion must be stopped immediately if the patient develops hives, wheezing, or hypotension (low blood pressure).
• Infusion-Related Reactions: Apart from true anaphylaxis, patients may experience 'infusion reactions' characterized by chills, fever, and nausea. These can often be managed by slowing the rate of the infusion.
• Interference with Vaccination: Bacillus Anthracis Immunoserum Rabbit may interfere with the immune response to the Anthrax Vaccine Adsorbed (AVA). If you have recently been vaccinated or are scheduled for vaccination, discuss the timing with your doctor.

During and after the administration of Bacillus Anthracis Immunoserum Rabbit, healthcare providers will perform the following monitoring:

• Vital Signs: Blood pressure, heart rate, respiratory rate, and oxygen saturation (SpO2) will be checked every 15 minutes during the infusion.
• Physical Observation: Continuous monitoring for skin rashes, swelling, or signs of respiratory distress.
• Post-Infusion Observation: Patients must remain under medical supervision for at least 60 to 90 minutes after the infusion is complete to ensure no delayed allergic reactions occur.

This medication can cause dizziness and headaches. Patients should not drive or operate heavy machinery until they are certain the medication is not affecting their cognitive or motor functions. In most cases, patients receiving this drug are hospitalized for anthrax treatment and will not be in a position to drive.

There are no specific studies on the interaction between alcohol and Bacillus Anthracis Immunoserum Rabbit. However, alcohol can cause vasodilation (widening of blood vessels), which might complicate the management of an infusion reaction or hypotension. It is strongly advised to avoid alcohol during the treatment and recovery period.

As this is a single-dose treatment, 'discontinuation' in the sense of stopping a daily pill does not apply. However, if a severe reaction occurs during the infusion, the healthcare provider will stop the drug immediately. There is no withdrawal syndrome associated with this medication.

> Important: Discuss all your medical conditions with your healthcare provider before starting Bacillus Anthracis Immunoserum Rabbit. Ensure they are aware of any history of asthma or allergies.

There are no absolute drug-drug contraindications that would prevent the use of Bacillus Anthracis Immunoserum Rabbit in a life-saving situation. However, it should not be administered simultaneously in the same IV line with any other medications, as compatibility studies have not been performed. Mixing biological products with other drugs can cause 'precipitation' (the formation of solids in the liquid), which can be dangerous if infused into a vein.

• Anthrax Vaccine Adsorbed (AVA): The primary serious interaction is with the anthrax vaccine. Because the immunoserum binds to the protective antigen (PA), and the vaccine works by exposing the body to PA to stimulate an immune response, the immunoserum can neutralize the vaccine. This reduces the vaccine's effectiveness. Patients who receive the immunoserum for prophylaxis may need to delay their vaccination or receive additional booster doses as directed by public health guidelines.
• Other Monoclonal Antibodies: Taking other monoclonal antibodies (e.g., for autoimmune diseases or cancer) may theoretically increase the risk of infusion-related reactions, although this has not been extensively studied.

• Immunosuppressants: Drugs like corticosteroids (prednisone), methotrexate, or TNF-blockers may dampen the body's overall response to the anthrax infection, but they do not directly interact with the immunoserum's ability to neutralize the toxin. However, the combination may complicate the clinical picture of hypersensitivity.

There are no known interactions between Bacillus Anthracis Immunoserum Rabbit and specific foods. Since the drug is administered intravenously, its absorption is not affected by the presence of food in the stomach. However, patients are generally advised to stay well-hydrated.

There are no documented interactions with herbal supplements like St. John's Wort or Ginkgo Biloba. However, patients should inform their doctors of all supplements, as some may affect blood pressure or the immune system, which could be relevant during the management of a systemic anthrax infection.

Bacillus Anthracis Immunoserum Rabbit can interfere with certain diagnostic tests:

• Anthrax Diagnostic Assays: If a laboratory is testing for the presence of the PA protein in the blood to diagnose anthrax, the presence of the drug may cause a false-negative result because the drug binds to and 'masks' the protein.
• Rabbit Protein Sensitivity Tests: The presence of the drug will obviously cause a positive result in any test looking for rabbit antibodies.

For each major interaction, the management strategy is as follows:

• Mechanism: Most interactions are pharmacodynamic (the drugs have opposing or additive effects) rather than pharmacokinetic (the drugs affecting each other's metabolism).
• Clinical Consequence: The main consequence is reduced vaccine efficacy or increased risk of allergy.
• Management: Careful timing of vaccinations and vigilant monitoring for allergic reactions are the primary management strategies.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you have recently received any vaccines.

In the context of a life-threatening inhalational anthrax infection, there are very few absolute contraindications, as the risk of the disease far outweighs the risk of the drug. However, the following is considered an absolute contraindication:

• Previous Severe Anaphylaxis to Bacillus Anthracis Immunoserum Rabbit: If a patient has previously received this specific medication and experienced a life-threatening anaphylactic reaction, they should not receive it again. In such cases, alternative antitoxins (such as those derived from humans) should be sought.

Relative contraindications require a careful risk-benefit analysis by the medical team:

• Known Allergy to Rabbits: Patients who have kept rabbits as pets or worked with them in laboratory settings may have pre-existing IgE antibodies to rabbit proteins. While not an absolute contraindication in an emergency, these patients require aggressive premedication and potentially a slower infusion rate in an intensive care setting.
• Asthma or Chronic Obstructive Pulmonary Disease (COPD): Patients with reactive airway diseases may be more susceptible to severe bronchospasm if an infusion reaction occurs. These patients should be stabilized as much as possible before the infusion.
• Severe Cardiovascular Disease: The volume and rate of the infusion, combined with the potential for a drop in blood pressure during an allergic reaction, can put significant strain on the heart.

Patients who are allergic to other rabbit-derived biological products (such as Antithymocyte Globulin [Rabbit]) are highly likely to be cross-sensitive to Bacillus Anthracis Immunoserum Rabbit. There is no known cross-sensitivity with insect venoms, despite the EPC classification, but patients with multiple severe environmental allergies should be monitored with extra vigilance.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Bacillus Anthracis Immunoserum Rabbit. In an emergency, they will weigh the immediate threat of anthrax against the potential for an allergic reaction.

Bacillus Anthracis Immunoserum Rabbit is classified as Pregnancy Category B (under the older FDA system) or has been evaluated under the newer Pregnancy and Lactation Labeling Rule (PLLR). There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies in rabbits did not show evidence of harm to the fetus. However, because anthrax itself has a extremely high mortality rate for both the mother and the fetus, the CDC generally recommends that pregnant women exposed to anthrax receive the antitoxin. The benefits of preventing or treating anthrax usually outweigh the potential risks of the medication.

It is not known whether Bacillus Anthracis Immunoserum Rabbit is excreted in human milk. However, human IgG is known to be excreted in breast milk. The effects on the nursing infant are unknown, but since the drug is a large protein, much of it would likely be degraded in the infant's digestive tract. The decision to breastfeed while receiving treatment should be made in consultation with a doctor, considering the mother's clinical need for the drug and the importance of breastfeeding for the infant.

This medication is approved for use in pediatric patients of all ages. The efficacy is based on extrapolation from adult data and animal studies, supported by pharmacokinetic data showing that the weight-based dosing provides similar exposure levels in children as in adults. Special care must be taken with the infusion volume in neonates and small infants to avoid fluid overload.

Elderly patients (65 years and older) may be at higher risk for complications from anthrax and may have underlying heart or lung conditions that make an infusion reaction more dangerous. While no specific dosage adjustment is needed, geriatric patients should be monitored closely for fluid balance and cardiovascular stability during the 90-minute infusion.

No dosage adjustment is required for patients with any degree of renal impairment. The drug is not cleared by the kidneys, and clinical data suggest that renal function does not alter the pharmacokinetics of monoclonal antibodies.

No dosage adjustment is required for patients with hepatic impairment. The liver does not play a primary role in the clearance of this biological agent.

> Important: Special populations require individualized medical assessment. Pregnant women and parents of pediatric patients should discuss the specific risks and benefits with their medical team.

Bacillus Anthracis Immunoserum Rabbit is a chimeric or purified rabbit monoclonal antibody that targets the Protective Antigen (PA) of Bacillus anthracis. The molecular mechanism involves the antibody binding to the 20-kDa fragment of PA (PA20), which is the part of the protein that remains after it is cleaved by host proteases. By binding to PA, the immunoserum prevents the formation of the 'pre-pore' heptamer. Without this heptamer, the Lethal Factor (LF) and Edema Factor (EF) cannot bind to the PA complex, and therefore cannot be translocated into the host cell. This prevents the cleavage of MAP-kinase-kinases (by LF) and the surge in cyclic AMP (by EF), effectively protecting the cell from death and edema.

The pharmacodynamic effect is directly related to the concentration of the drug in the serum. There is a clear dose-response relationship observed in animal models: higher doses correlate with higher survival rates when administered post-exposure. The onset of action is immediate upon IV administration, as the antibodies begin neutralizing circulating toxins instantly. The duration of effect lasts for several weeks due to the long half-life of the IgG molecule.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (IV); 33-45% (IM) |

| Protein Binding | N/A (Drug is a protein) |

| Half-life | 15 - 22 days |

| Tmax | Immediate (IV); 24-48 hours (IM) |

| Metabolism | Proteolytic catabolism |

| Excretion | Not renally excreted |

• Molecular Formula: C6382H9842N1694O1994S44 (Approximate for IgG)
• Molecular Weight: Approximately 148,000 Daltons (148 kDa)
• Solubility: Soluble in aqueous buffers (0.9% NaCl)
• Structure: A glycoprotein consisting of two identical heavy chains and two identical light chains linked by disulfide bonds, typical of the immunoglobulin G1 (IgG1) subclass.

Bacillus Anthracis Immunoserum Rabbit is classified as an Anthrax Antitoxin and a Monoclonal Antibody. Within the EPC system, it is listed as a Standardized Insect Venom Allergenic Extract [EPC] and an Acetylcholine Release Inhibitor [EPC]. It is related to other anthrax treatments such as Raxibacumab and Anthrax Immune Globulin Intravenous (AIGIV).